• Explore /
  • Poster
  • / Phase 3 LITESPARK-022: Pembrolizumab (pembro) plus hypoxia-inducible factor 2α (HIF-2α) inhibitor belzutifan as adjuvant treatment for clear cell renal cell carcinoma (ccRCC).

Phase 3 LITESPARK-022: Pembrolizumab (pembro) plus hypoxia-inducible factor 2α (HIF-2α) inhibitor belzutifan as adjuvant treatment for clear cell renal cell carcinoma (ccRCC).

Abstract Poster

Authors

Toni Choueiri

Toni K. Choueiri

Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA

Toni K. Choueiri , Jens Bedke , Jose A. Karam , Rana R. McKay , Robert J. Motzer , Sumanta Monty Pal , Cristina Suárez , Robert Uzzo , Hong Liu , Joseph E. Burgents , Manish Sharma , Thomas Powles

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers

Track

Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT05239728

Citation

J Clin Oncol 41, 2023 (suppl 6; abstr TPS748)

DOI

10.1200/JCO.2023.41.6_suppl.TPS748

Abstract #

TPS748

Poster Bd #

N6

Abstract Disclosures

Similar Posters

First Author: Toni K. Choueiri

First Author: Toni K. Choueiri

First Author: Robert J. Motzer

First Author: Toni K. Choueiri